BACKGROUND. Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality after allogeneic bone marrow transplantation. We conducted a controlled trial of ganciclovir for the early treatment of CMV infection in asymptomatic recipients of bone marrow transplants whose surveillance cultures for CMV became positive. METHODS. Bone marrow--allograft recipients who were seropositive for CMV antibodies or who received seropositive marrow were screened for CMV excretion by culture of throat swabs, blood, urine, or bronchoalveolar-lavage fluid. In this double-blind trial, 72 patients who had marrow engraftment and were excreting virus were randomly assigned to receive either placebo or ganciclovir (5 mg per kilogram of body weight twice a day for one week, followed by 5 mg per kilogram per day) for the first 100 days after transplantation. Patients were followed for the development of biopsy-confirmed CMV disease, ganciclovir-related toxicity, and survival. RESULTS. Between assignment to the study drug and day 100 after transplantation, CMV disease developed in only 1 of the 37 patients assigned to receive ganciclovir (3 percent), but in 15 of the 35 patients assigned to receive placebo (43 percent, P less than 0.00001). The ganciclovir recipients had rapid suppression of virus excretion; 85 percent had negative cultures after one week of treatment, as compared with 44 percent of the placebo group (P = 0.001). The principal toxic reaction was neutropenia; 11 ganciclovir recipients had an absolute neutrophil count below 0.75 x 10(9) per liter, as compared with 3 placebo recipients (P = 0.052). Treatment was discontinued in 11 ganciclovir recipients and 1 placebo recipient because of neutropenia (P = 0.003). After treatment was stopped, the neutrophil count recovered in all patients. Overall survival was significantly greater in the ganciclovir group than in the placebo group both 100 days and 180 days after transplantation (P = 0.041 and 0.027, respectively). CONCLUSIONS. Early treatment with ganciclovir in patients with positive surveillance cultures reduces the incidence of CMV disease and improves survival after allogeneic bone marrow transplantation.
Source Information
Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
This article has been cited by other articles:
Mehta, J.
(2008). Cytomegalovirus: time for a requiem?. Blood
111: 5265-5266
[Full Text]
Marty, F. M., Bryar, J., Browne, S. K., Schwarzberg, T., Ho, V. T., Bassett, I. V., Koreth, J., Alyea, E. P., Soiffer, R. J., Cutler, C. S., Antin, J. H., Baden, L. R.
(2007). Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood
110: 490-500
[Abstract][Full Text]
Einsele, H., Reusser, P., Bornhauser, M., Kalhs, P., Ehninger, G., Hebart, H., Chalandon, Y., Kroger, N., Hertenstein, B., Rohde, F., for the EBMT Working Group on Infectious Disease,
(2006). Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood
107: 3002-3008
[Abstract][Full Text]
Kruger, W. H., Bohlius, J., Cornely, O. A., Einsele, H., Hebart, H., Massenkeil, G., Schuttrumpf, S., Silling, G., Ullmann, A. J., Waldschmidt, D. T., Wolf, H.-H.
(2005). Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol
16: 1381-1390
[Abstract][Full Text]
Herrmann, B., Cavaglia Larsson, V., Rubin, C.-J., Sund, F., Eriksson, B.-M., Arvidson, J., Yun, Z., Bondeson, K., Blomberg, J.
(2004). Comparison of a Duplex Quantitative Real-Time PCR Assay and the COBAS Amplicor CMV Monitor Test for Detection of Cytomegalovirus. J. Clin. Microbiol.
42: 1909-1914
[Abstract][Full Text]
Cordonnier, C., Chevret, S., Legrand, M., Rafi, H., Dhedin, N., Lehmann, B., Bassompierre, F., Gluckman, E., for the GREFIG Study Group*,
(2003). Should Immunoglobulin Therapy Be Used in Allogeneic Stem-Cell Transplantation? A Randomized, Double-Blind, Dose Effect, Placebo-Controlled, Multicenter Trial. ANN INTERN MED
139: 8-18
[Abstract][Full Text]
Gerna, G., Lilleri, D., Baldanti, F., Torsellini, M., Giorgiani, G., Zecca, M., De Stefano, P., Middeldorp, J., Locatelli, F., Revello, M. G.
(2003). Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood
101: 5053-5060
[Abstract][Full Text]
Boeckh, M., Leisenring, W., Riddell, S. R., Bowden, R. A., Huang, M.-L., Myerson, D., Stevens-Ayers, T., Flowers, M. E. D., Cunningham, T., Corey, L.
(2003). Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood
101: 407-414
[Abstract][Full Text]
Weinberg, A., Schissel, D., Giller, R.
(2002). Molecular Methods for Cytomegalovirus Surveillance in Bone Marrow Transplant Recipients. J. Clin. Microbiol.
40: 4203-4206
[Abstract][Full Text]
Veys, P., Owens, C.
(2002). Respiratory infections following haemopoietic stem cell transplantation in children. Br Med Bull
61: 151-174
[Abstract][Full Text]
Reusser, P., Einsele, H., Lee, J., Volin, L., Rovira, M., Engelhard, D., Finke, J., Cordonnier, C., Link, H., Ljungman, P.
(2002). Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood
99: 1159-1164
[Abstract][Full Text]
Griffiths, P. D.
(2002). The treatment of cytomegalovirus infection. J Antimicrob Chemother
49: 243-253
[Abstract][Full Text]
Griscelli, F., Barrois, M., Chauvin, S., Lastere, S., Bellet, D., Bourhis, J.-H.
(2001). Quantification of Human Cytomegalovirus DNA in Bone Marrow Transplant Recipients by Real-Time PCR. J. Clin. Microbiol.
39: 4362-4369
[Abstract][Full Text]
Solano, C., Munoz, I., Gutierrez, A., Farga, A., Prosper, F., Garcia-Conde, J., Navarro, D., Gimeno, C.
(2001). Qualitative Plasma PCR Assay (AMPLICOR CMV Test) versus pp65 Antigenemia Assay for Monitoring Cytomegalovirus Viremia and Guiding Preemptive Ganciclovir Therapy in Allogeneic Stem Cell Transplantation. J. Clin. Microbiol.
39: 3938-3941
[Abstract][Full Text]
Cornelissen, J. J., Carston, M., Kollman, C., King, R., Dekker, A. W., Lowenberg, B., Anasetti, C.
(2001). Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood
97: 1572-1577
[Abstract][Full Text]
Peggs, K., Verfuerth, S., Mackinnon, S.
(2001). Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood
97: 994-1000
[Abstract][Full Text]
Boivin, G., Bélanger, R., Delage, R., Béliveau, C., Demers, C., Goyette, N., Roy, J.
(2000). Quantitative Analysis of Cytomegalovirus (CMV) Viremia Using the pp65 Antigenemia Assay and the COBAS AMPLICOR CMV MONITOR PCR Test after Blood and Marrow Allogeneic Transplantation. J. Clin. Microbiol.
38: 4356-4360
[Abstract][Full Text]
Poirier-Toulemonde, A.-S., Milpied, N., Cantarovich, D., Morcet, J.-F., Billaudel, S., Imbert-Marcille, B.-M.
(2000). Clinical Relevance of Direct Quantification of pp65 Antigenemia Using Flow Cytometry in Solid Organ and Stem Cell Transplant Recipients. J. Clin. Microbiol.
38: 3143-3149
[Abstract][Full Text]
Machida, U., Kami, M., Fukui, T., Kazuyama, Y., Kinoshita, M., Tanaka, Y., Kanda, Y., Ogawa, S., Honda, H., Chiba, S., Mitani, K., Muto, Y., Osumi, K., Kimura, S., Hirai, H.
(2000). Real-Time Automated PCR for Early Diagnosis and Monitoring of Cytomegalovirus Infection after Bone Marrow Transplantation. J. Clin. Microbiol.
38: 2536-2542
[Abstract][Full Text]
Nitsche, A., Steuer, N., Schmidt, C. A., Landt, O., Ellerbrok, H., Pauli, G., Siegert, W.
(2000). Detection of Human Cytomegalovirus DNA by Real-Time Quantitative PCR. J. Clin. Microbiol.
38: 2734-2737
[Abstract][Full Text]
(2000). Management of herpes virus infections following transplantation. J Antimicrob Chemother
45: 729-748
[Full Text]
Caliendo, A. M., St. George, K., Kao, S.-Y., Allega, J., Tan, B.-H., LaFontaine, R., Bui, L., Rinaldo, C. R.
(2000). Comparison of Quantitative Cytomegalovirus (CMV) PCR in Plasma and CMV Antigenemia Assay: Clinical Utility of the Prototype AMPLICOR CMV MONITOR Test in Transplant Recipients. J. Clin. Microbiol.
38: 2122-2127
[Abstract][Full Text]
Gerna, G., Baldanti, F., Lilleri, D., Parea, M., Alessandrino, E., Pagani, A., Locatelli, F., Middeldorp, J., Revello, M. G.
(2000). Human Cytomegalovirus Immediate-Early mRNA Detection by Nucleic Acid Sequence-Based Amplification as a New Parameter for Preemptive Therapy in Bone Marrow Transplant Recipients. J. Clin. Microbiol.
38: 1845-1853
[Abstract][Full Text]
Broers, A. E. C., van der Holt, R., van Esser, J. W. J., Gratama, J.-W., Henzen-Logmans, S., Kuenen-Boumeester, V., Lowenberg, B., Cornelissen, J. J.
(2000). Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood
95: 2240-2245
[Abstract][Full Text]
Pellegrin, I., Garrigue, I., Binquet, C., Chene, G., Neau, D., Bonot, P., Bonnet, F., Fleury, H., Pellegrin, J.-L.
(1999). Evaluation of New Quantitative Assays for Diagnosis and Monitoring of Cytomegalovirus Disease in Human Immunodeficiency Virus-Positive Patients. J. Clin. Microbiol.
37: 3124-3132
[Abstract][Full Text]
Balfour, H. H.
(1999). Antiviral Drugs. NEJM
340: 1255-1268
[Full Text]
Greinix, H. T., Volc-Platzer, B., Rabitsch, W., Gmeinhart, B., Guevara-Pineda, C., Kalhs, P., Krutmann, J., Honigsmann, H., Ciovica, M., Knobler, R. M.
(1998). Successful Use of Extracorporeal Photochemotherapy in the Treatment of Severe Acute and Chronic Graft-Versus-Host Disease. Blood
92: 3098-3104
[Abstract][Full Text]
Boeckh, M., Boivin, G.
(1998). Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications. Clin. Microbiol. Rev.
11: 533-554
[Abstract][Full Text]
Salzberger, B., Bowden, R. A., Hackman, R. C., Davis, C., Boeckh, M.
(1997). Neutropenia in Allogeneic Marrow Transplant Recipients Receiving Ganciclovir for Prevention of Cytomegalovirus Disease: Risk Factors and Outcome. Blood
90: 2502-2508
[Abstract][Full Text]
Diamond, D. J., York, J., Sun, J.-Y., Wright, C. L., Forman, S. J.
(1997). Development of a Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection. Blood
90: 1751-1767
[Abstract][Full Text]
Reusser, P., Attenhofer, R., Hebart, H., Helg, C., Chapuis, B., Einsele, H.
(1997). Cytomegalovirus-Specific T-Cell Immunity in Recipients of Autologous Peripheral Blood Stem Cell or Bone Marrow Transplants. Blood
89: 3873-3879
[Abstract][Full Text]
Crumpacker, C. S.
(1996). Ganciclovir. NEJM
335: 721-729
[Full Text]
Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., Riddell, S. R.
(1995). Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor. NEJM
333: 1038-1044
[Abstract][Full Text]
Armitage, J. O.
(1994). Bone Marrow Transplantation. NEJM
330: 827-838
[Full Text]
Previous
